CENTRE FOR RESPIRATORY DISEASES RESEARCH (CRDR) NAIROBI

Acqering samples for CD4 count using FACSCaliber

Overview

Background

The Centre for Respiratory Diseases Research (CRDR) is a centre of the Kenya Medical Research Institute (KEMRI).

The centre was started the early fifties when Tuberculosis Research was carried out under the auspices of East African Community: Kenya, Uganda and Tanganyika (Tanzania) all under British rule.

The present CRDR premises were constructed in the early seventies with its extension put up in 1980.

Staff Establishment

The Centre comprises 50 members of staff. 26 Research/scientific staff and 24 Administrative/support staff.

Mission

To conduct research on respiratory diseases of public health importance in order to improve the health of Kenyans.

Vision

To be a leading Centre of excellence in Respiratory Diseases Research nationally, towards the improvement of humanity health

Mandates/ Functions

  1. TB epidemiology, case finding and holding, immunization, pharmacotherapy of TB and pharmacoepidemiology of drug resistance TB in HIV infection.
  2. Non-TB respiratory diseases: high priority pathologies eg. Bronchial asthma, industrial respiratory implications and acute respiratory infections.
  3. Lung function.
  4. Immunology of the TB and allergic conditions.
  5. Environmental and occupational health.

Core Values

  1. Good Corporate Governance
  2. Professionalism
  3. Creativity and Innovation
  4. Sanctity of life

Ongoing Projects (Jan 2020 - July 2020 )

  1. SERU A Randomized Double Blind, Parallel-Group, Multicenter, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-occlusive Crises in pediatric patients with Sickle Cell Disease
  2. An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials
  3. SERU No.3438  An Open Label Extension Study of GBT 440 Administered Orally to patients with Sickle Cell Disease Who Have Participated in GBT 440 Clinical Trial
  4. SERU No. 3720 A Randomized Double Blind, Parallel-Group, Multicenter, Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-occlusive Crises in pediatric patients with Sickle Cell Disease (HESTIA 3)
  5. SERU No. 3630  –  A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ  in African Patients with Uncomplicated Plasmodium falciparum Malaria
  6. SERU 3681 – “Prevalence of pulmonary tuberculosis and HIV among long distance truck drivers and commercial sex workers in Mlolongo, Machakos County.”
  7. SERU 3631 – Pulmonary and latent Tuberculosis in public transportation in Nairobi County, Kenya.
  8. SERU 3662- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease and an Open-label Study in Infants with Sickle Cell Disease. (HOPE Kids2).
  9. SERU 3988 –  Epidemiologic,Transmission, Immunogenetic and Diagnostic studies of Mycobacterium Tuberculosis
  10. SERU 3959 – Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants (Shan 6)
  11. SERU 3977 -A multicentre, phase III, double-blind, randomized, active-controlled study to evaluate the efficacy and safety of VPM1002 in comparison with BCG in prevention of Mycobacterium tuberculosis infection in new-born infants
  12. SERU 2519 – The burden of Obstructive Lund Diseases in Nairobi and its environs
  13. SERU 3944 – Non-communicable lung disease in Kenya: from burden and early life determinants to participatory inter-disciplinary solutions; The TUPUMUE Study
  14. SERU 3761 – A cross-sectional study, of the characteristics of adults with chronic respiratory symptoms attending outpatient departments at Mbagathi Hospital in Nairobi, Kenya : A Multi- Center study
  15. SERU – 3717 – Chronic respiratory symptoms in adults and children in Kenya: how do health systems respond and what are the opportunities for health system strengthening.
  16. SERU 3840 – The Utility of Clinician-Performed Cardiopulmonary Ultrasound Assessment of the Acutely Breathless Patient: Breathlessness Early Detection with Ultrasound trial (BED-US Trial)
  17. SERU  3887 – Role of IL-17 Cytokine networks in TB relapse due to HIV7.
  18. SERU 3674: A Comparative Study on the Quality of Life of Leprosy Patients, their Household Contacts and the Public Health Implications of Zoonotic
  19. SERU 3234 –   Geomatic Mapping Of Indoor Fungi And Their Associated Respiratory Health Effects In Residential Environments, In Nairobi and Busia Urban Counties, Kenya.clinical sources in Nairobi
  20. SERU 3742 Genotypic and phenotypic characterization of Fusarium species from soils in Mycotoxic “hot zones” in Eastern County-Kenya

 

Completed Projects

COMING SOON

Tuberculosis Laboratory

Mycology Laboratory

KEMRI - VCT

CRDR Clinical Trial Annex

Operational Research

Non-communicable Disease (NCDs)

Dr. Videlis Nduba -Deputy Director, CRDR

Dr. Videlis Nduba is a Deputy Director in charge of the Center for Respiratory Diseases Research (CRDR).
He has worked at the Institute for over 13 years with his work focusing in TB Research including developing tuberculosis epidemiological capacity to conduct phase II and III TB vaccine trials in adolescents and infants, diagnostics for infant TB, and epidemiology of TB in adolescents. He was a principal investor of a double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402) in infants, of which Kenya was one of four countries participating in this trial.

Dr. Nduba has conducted two TB vaccine trials, one in infants and the other in adults that included bio banking protocols and extensive immunology sample collection and processing.

He has also lead a TB drug treatment trial that examined at a novel new treatment- MPaZ for shortening TB treatment from six to four months for drug sensitive TB. This research has included developing extensive networks with the TB treatment program, community networks with TB ambassadors and community health.

1

Asiko Ongaya

Ms. Asiko is trained as a medical laboratory scientist (Bsc) and Mycobacteriologist (Msc) and currently undertaking a PhD studies in Microbiology. She has seven years of experience in Infectious Disease Research (especially in TB). Her research goals include to new TB diagnostics, TB drug resistance, TB drugs and to understand the protective host response to Mycobacterium tuberculosis (M.tb), especially as compromised by HIV. Ms. Asiko is currently working as Research Officer at the Centre for Respiratory Diseases Research, Kenya Medical Research Institute (KEMRI), involved in various research projects as a Principle Investigator and co-investigator.

Untitled-2

Dr. Jane Rahedi Ong’ang’o-Senior Research Officer

Dr. Jane Rahedi Ong’ang’o is a Public Health Specialist with interest in Programme Implementation and Operational Research of interventions geared towards control of both Communicable and Non-Communicable Conditions.
Currently she is a Senior Research Scientist at CRDR focusing on a wide scope of Public Health Research. Previously she worked as a National Programme coordinator for CDC funded HIV/TB programmes in various parts of Kenya contracted by International Medical Corps (Kenya).
In these programmes she was able to utilize community approaches to enhance scale up and use of HIV/TB services. She has been involved in implementation research and evaluation of various aspects of programme implementation. She closely works with the Ministry of Health in the National TB, Leprosy & Lung Disease Program. In the area of research, she has been a Principal investigator of various population-based surveys and has also served as a research team coordinator. In both her work areas of programme implementation and implementation research, she continues to play a role in capacity building of health workers.
Dr. Ong’ang’o has keen interest in the area of program evaluation and reviews and has previously been involved in the review of Kenya National TB program and her areas of focus are in programmatic management and Research monitoring and evaluation

Picture1

Mr. Lawrence N. Thiong’o-Research Officer

MSc in Medical Microbiology, BSc in Biomedical Sciences and Ordinary Diploma in Laboratory Technology

Involved in Clinical Trial in the comparison of two drugs Dolutegravir and Kaletra as second-line treatment in HIV-infected patients failing first line therapy-sponsored by GloxoSmithkline.

Leadership & Management in Health Sponsored by the University Of Washington.
Developed aManuscript entitled: Molecular characterization of multi-Drug resistant Escherichia coli isolated from urine samples in Mater Hospital, Nairobi, Kenya. Sent for
publication in East African Journal of Pathology (EAJP)

Involved in Family AIDS Care and Educational Services (FACES) Project. Responsible for Immunological and Microbiological work.

Principal investigator: Molecular characterization of multi- drug resistant Escherichia coli isolated from urine samples in Mater Hospital, Nairobi, Kenya

Picture1

Ms. Olga Mukasia Mashedi-Research officer

1.Academic and professional qualifications
MSc. Mycology and Bachelor Of Science in Microbiology
2.Professional/work /research experience
Mycologist area of interest in the field Respiratory Mycology
Filamentous fungi, non communicable diseases.
Research Grants/Current/Previous last three (3) years and State if PI/Co-Investigator/Support Staff
1. Principal investigator; Geomatic mapping of indoor fungi and their associated respiratory health effects in residential environments, in Nairobi and Busia urban counties-Kenya.
2. Principal investigator in Molecular characterization and antifungal drug profile of dermatophytes isolated from clinical sources in Nairobi- Kenya.
3. Principal investigator in the project titled indoor fungi and their associated health effects in residential environments in Nairobi Kenya
4. Co-investigator in the project titled: Public Mycotoxicological food safety in Kenyan Cereals.
5. Co- Investigator in the project titled: Molecular characterization and detection of Mycotoxin producing genes in mycotoxigenic fungi from Kenya cereals

Picture1

Ms. Sophie W. Matu-Research Officer

Academic and professional qualifications
B.Sc Biological Sciences (Jomo Kenyatta University- JKUAT) M.Sc Infectious Diseases Diagnosis (Kenyatta University), PhD student (Jomo Kenyatta University- JKUAT)

Professional/work /research experience
Laboratory TB diagnosis with special interest in TB/HIV co-infection, drug resistant TB and NCDs
Extra Responsibilities
Center Biosafety Officer
ISO 9001:2008 QMS officer
Member National Biosecurity Advisory Committee
Member Healthcare Waste Management -Technical Working Group (HCWM-TWG)
Member Climate Change Technical Working Group
KEMRI Climate change desk member

Selected Publications /papers presented
– Matu S.W and Ernest Juma. Improved Ziehl-Neelsen Microscopy: Bleach Sputum Smear Negative Specimens after Centrifugation. Journal of Life Sciences, ISSN 1934-7391, USA. June 2013, Vol. 7, No. 6, pp. 607-612.
– Matu S.W., Okari J., Ong’ang’o J., Kipruto H and Sitienei J. Evaluation of GenoType MTBDR for molecular detection mycobacterium tuberculosis multi-drug resistant strains at the Tuberculosis Central Reference Lab. Int J Tuberc Lung Dis 2012; 16(12) supp 1: PC-692-16.
– Okari J., Matu S.W., Ong’ang’o J., Kipruto H and Sitienei J. Drug Resistance among previously treated Pulmonary Patients in Kenya. Keystone Symposia; Drug Resistance and persistence in tuberculosis May 13-18, 2012. Poster 226.

Research Grants/Current/Previous last three (3) years
– Principle Investigator: (SSC 2948). Evaluation of the diagnostic accuracy and utility of Lateral Flow Urine Lipoarabinomannan (LAM) Test for Diagnosis of Tuberculosis in HIV-Positive presumptive TB cases
– Investigator/study coordinator: (SSC2967). A Phase IIIb, randomized, open-label study of the safety and antiviral activity of dolutegravir compared to lopinavir/ritonavir both administered with dual nucleoside reverse transcriptase inhibitor therapy in HIV-1 infected adult subjects with treatment failure on first line therapy
– Investigator/study coordinator: (SSC 2519). The burden of obstructive lung Diseases in Nairobi and its environs. Sponsor: Government of Kenya
– Research Grants/Current/Previous last three (3) years.
– State if PI/Co-Investigator/Support Staff

Contact Info

CENTRE FOR RESPIRATORY DISEASES RESEARCH,
P.O.Box 47855-0100.
Nairobi, Kenya

TEL       +254-020-2719601 / +254-020-2724264/5

E-mail: crdrkemri@gmail.com.

Location